Compare Gilead Sciences, Inc. (GILD) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Gilead Sciences, Inc. trades at $132.77 (market cap $163.51B), while iShares 1 3 Year Treasury Bond ETF trades at $81.98. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while iShares 1 3 Year Treasury Bond ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| GILD | SHY | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Fixed Income |
52-Week High | $155.80 | $83.18 |
52-Week Low | $108.22 | $81.79 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
SHY, a US stock, trades at $81.985 with a slight 0.07% daily gain. Technical indicators show a mixed but overall bullish signal, with moving averages bearish and oscillators neutral. Recent corporate actions include consistent dividend payments of $0.24. The stock's financial ratios are unavailable in the provided data, limiting fundamental analysis. Market sentiment is influenced by broader bond market trends and Federal Reserve policy expectations, as highlighted in recent financial news.
The outlook for SHY is cautious due to limited fundamental data and reliance on macroeconomic factors. Investment opportunities may arise from steady dividend yields, but risks include interest rate volatility and economic uncertainty. Investors should seek updated financials for a comprehensive view, as current analysis hinges on technical signals and external market conditions rather than company-specific performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
